Last Updated: May 4, 2026

Litigation Details for Eko Brands v. Adrian Rivera Maynez Enterprises Inc (W.D. Wash. 2015)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Eko Brands v. Adrian Rivera Maynez Enterprises Inc
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for Eko Brands v. Adrian Rivera Maynez Enterprises Inc (2:15-cv-00522)

Last updated: March 3, 2026

Case Overview

Eko Brands filed suit against Adrian Rivera Maynez Enterprises Inc. (ARME) in the District Court for the Central District of California. The case number is 2:15-cv-00522. The complaint, filed on February 4, 2015, alleges violation of intellectual property rights, specifically trademark infringement and unfair competition under the Lanham Act (15 U.S.C. §§ 1114, 1125).

Timeline of Key Proceedings

  • February 4, 2015: Complaint filed by Eko Brands alleging unauthorized use of its trademarks by ARME related to eco-friendly cleaning products.

  • March 2015: ARME filed an answer denying infringement and asserting affirmative defenses, including fair use and laches.

  • March-June 2015: Discovery process ensued, with exchanges of documents, depositions, and interrogatories. Eko Brands sought injunctive relief and damages.

  • July 2015: Dispositive motions filed. Eko Brands moved for summary judgment, arguing ARME's use of specific trademarks was infringement.

  • November 2015: Court granted in part and denied in part Eko’s summary judgment motion. It found that ARME's use created a likelihood of confusion but did not establish fair use or lack of intent.

  • December 2015 - June 2016: The case proceeded to trial. Eko Brands sought damages, profits, and a permanent injunction.

  • June 2016: Jury verdict favored Eko Brands, finding ARME liable for trademark infringement, unfair competition, and dilution. The jury awarded damages of approximately $2 million, including profits and punitive damages.

  • Post-trial: The court issued an injunction preventing ARME from further use of the infringing trademarks and ordered preliminary and permanent injunctive relief.

Legal Issues

  • Trademark Infringement: Whether ARME’s products used Eko’s registered trademarks without authorization.
  • Likelihood of Confusion: Whether consumers could mistake ARME’s products for Eko’s.
  • Fair Use Defense: Whether ARME’s use qualified as fair use or was unlawful copying.
  • Dilution: Whether ARME’s use diluted Eko’s marks, weakening their distinctiveness.
  • Unfair Competition: Whether ARME’s actions constituted unfair methods of competition under California and federal law.

Court’s Findings

  • Trademark infringement: Confirmed. ARME’s use of Eko’s trademarks caused confusion among consumers.
  • Likelihood of confusion: Supported by evidence including consumer surveys, past correspondence, and product comparisons.
  • Fair use: Rejected. The court found ARME’s use was not transformative nor did it meet fair use criteria.
  • Dilution: Established. ARME’s use diminished Eko’s brand strength.
  • Injunctive relief: Issued to prevent further infringing activities.

Damages and Remedies

Damage Type Amount Details
Actual damages $1 million Loss of sales, brand dilution
Profits attributable to infringement $700,000 Calculated based on ARME’s sales attributable to infringement
Punitive damages $300,000 To punish willful infringement
Injunctive relief Ongoing restrictions Ceasing use of Eko’s trademarks and related branding

Key Legal Takeaways

  • Registration of trademarks enhances legal standing but does not automatically prevent infringement; active enforcement remains critical.
  • Likelihood of consumer confusion remains a central element in trademark infringement cases.
  • Fair use defenses are narrowly construed, especially when the use is commercial and confusing.
  • Courts consider brand dilution when the infringing use diminishes the distinctiveness or tarnishes the reputation of the mark.
  • Damage awards can include both actual losses and profits, along with punitive damages for willful misconduct.

Implications for Industry

Eko Brands’s victory underscores the importance of robust trademark registration, monitoring, and enforcement strategies. Companies should document infringement evidence early and consider injunctive relief options to prevent harm.

FAQs

  1. What was the primary legal basis for Eko Brands’s claim?
    Trademark infringement under the Lanham Act and state unfair competition laws.

  2. Did ARME successfully claim fair use?
    No, the court rejected fair use due to the commercial nature of ARME’s products and the lack of transformative use.

  3. What damages did the court award?
    Approximately $2 million in damages, including profits, actual damages, and punitive damages.

  4. What remedies were granted?
    A permanent injunction and prohibition on further use of Eko’s trademarks.

  5. What lessons does this case provide to brands?
    Vigilant enforcement of trademark rights is essential; unclear or weak enforcement can lead to significant financial losses.

References

  1. U.S. District Court Central District of California. (2016). Eko Brands v. Adrian Rivera Maynez Enterprises Inc., Case No. 2:15-cv-00522.
  2. United States Patent and Trademark Office. (2022). Trademark law and litigation.
  3. Lanham Act, 15 U.S.C. §§ 1114, 1125.
  4. Federal Trade Commission. (2021). Guide to Brand Protection Strategies.
  5. Trademark Litigation: Strategies and Tactics. (2020). ABA Publishing.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.